S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

$13.53
+0.13 (+0.97%)
(As of 02/23/2024 ET)
Today's Range
$13.41
$13.64
50-Day Range
$12.03
$14.52
52-Week Range
$9.70
$14.57
Volume
7.67 million shs
Average Volume
2.96 million shs
Market Capitalization
$3.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.20

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
27.1% Upside
$17.20 Price Target
Short Interest
Bearish
8.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.25mentions of Amicus Therapeutics in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$3.87 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.44) to $0.06 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.67 out of 5 stars

Medical Sector

262nd out of 939 stocks

Pharmaceutical Preparations Industry

116th out of 438 stocks


FOLD stock logo

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Stock Price History

FOLD Stock News Headlines

Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Why Banks Could See a "Cash Frenzy" on March 11
He called the Lehman Brothers collapse in 2008… the Bitcoin crash in 2018… and the inflation crisis of 2022. Now, he's warning that the 2023 banking crisis is not over yet. Instead, we could see a cash frenzy at banks as soon as March 11. Do NOT buy another stock until you
Amicus Therapeutics FY23 Revenue Climbs
The Analyst Landscape: 4 Takes On Amicus Therapeutics
FOLD Jan 2024 22.000 call
Stifel Nicolaus Reaffirms Their Buy Rating on Amicus (FOLD)
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/23/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
484
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$17.20
High Stock Price Target
$20.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+27.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-50.61%

Debt

Sales & Book Value

Annual Sales
$329.23 million
Book Value
$0.44 per share

Miscellaneous

Free Float
287,088,000
Market Cap
$3.97 billion
Optionable
Optionable
Beta
0.77

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price target for 2024?

5 Wall Street analysts have issued 12-month price objectives for Amicus Therapeutics' stock. Their FOLD share price targets range from $11.00 to $20.00. On average, they predict the company's stock price to reach $17.20 in the next year. This suggests a possible upside of 27.1% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the start of the year. Since then, FOLD shares have decreased by 4.7% and is now trading at $13.53.
View the best growth stocks for 2024 here
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our FOLD earnings forecast
.

How can I listen to Amicus Therapeutics' earnings call?

Amicus Therapeutics will be holding an earnings conference call on Wednesday, February 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The biopharmaceutical company earned $103.50 million during the quarter, compared to analyst estimates of $102.30 million. Amicus Therapeutics had a negative net margin of 46.61% and a negative trailing twelve-month return on equity of 147.61%. The firm's revenue was up 26.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.12) EPS.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $399.4 million-$399.4 million, compared to the consensus revenue estimate of $396.5 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.72%), Palo Alto Investors LP (3.54%), Fiera Capital Corp (1.73%), Northern Trust Corp (0.97%), Norges Bank (0.86%) and Novo Holdings A S (0.85%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 2/23/2024 by MarketBeat.com Staff